CDKN2A and neoplasm: Mutant KRAS drives tumor progression by activating downstream cell proliferation pathways, immunosuppression, and cell metabolism reprogramming, which in combination with loss of function alterations in tumor suppressor genes such as TP53, SMAD4, and CDKN2A, fuels PDAC tumor growth and metastasis3,4.